Genetic markers anticipate response to citalopram in a majority of patients.

Objective: Scientists have concluded that genetic profiles cannot predict a large percentage of variation in response to citalopram, a common antidepressant. Using the same data, we examined if a different conclusion can be arrived at when the results are personalized to fit specific patients.

Methods: We used data available through the Sequenced Treatment Alternatives to Relieve Depression database.

Improved Statistical Methods are Needed to Advance Personalized Medicine.

Common methods of statistical analysis, e.g. Analysis of Variance and Discriminant Analysis, are not necessarily optimal in selecting therapy for an individual patient.